Scientists develop simple blood test to track tumour evolution in cancer patients

May 3, 2013, University of Cambridge
Credit: Alila Medical Images - Fotolia

By tracking changes in patients' blood, Cambridge scientists have created a new way of looking at how tumours evolve in real-time and develop drug resistance. The research was published in the print edition of Nature today.

Scientists at the Cancer Research UK Cambridge Institute at the University of Cambridge used traces of tumour DNA, known as circulating tumour DNA (ctDNA), found in ' blood to follow the progress of the disease as it changed over time and developed resistance to chemotherapy treatments.

For the study, which was co-directed by Dr James Brenton, Professor Carlos Caldas, and Dr Nitzan Rosenfeld from the University's Cancer Research UK Cambridge Institute, they followed six patients with advanced breast, ovarian and lung cancers and took blood samples, over one to two years. They then focused analysis on those samples that contained relatively higher concentrations of tumour ctDNA,

By looking for changes in the tumour ctDNA before and after each course of treatment, they were able to identify changes in the tumour's DNA that were likely linked to drug resistance following each treatment session.

Using this new method they were able to identify several changes linked to drug-resistance in response to such as () which is used to treat ovarian, breast and lung cancers, tamoxifen which is used to treat oestrogen-positive breast cancers and transtuzumab () which is used to treat HER2 positive breast cancers.

The researchers hope this new approach could facilitate research on how develop resistance to some of our most effective chemotherapy drugs as well as providing an alternative to current methods of collecting tumour DNA – by taking a sample direct from the tumour – a much more difficult and .

Dr Rosenfeld said: "Tumours are constantly changing and evolving which helps them develop a resistance to many of the drugs we currently give patients to treat their disease. We've shown that a very simple blood test can be used to collect enough tumour DNA to suggest to us what parts of the cancer's genetic code is changing and creating tumour resistance to chemotherapy or biologically-targeted therapies.

"We hope that our discoveries can pave the way to helping us understand how cancers develop drug resistance as well as identifying new potential targets for future cancer drugs."

Dr Brenton added: "Importantly, this advance means that we will be able to screen a much larger number of genes in the blood to test if specific genetic changes in the cancer explain resistance to treatment. The low cost and high acceptability of a blood sample means that this can be done across hundreds or thousands of patients. This is vital to discover reliable clinical biomarkers."

Professor Caldas said: "The tracking of different cancer clones in real time using a liquid biopsy will have enormous value to identify in the clinic and adjust therapy accordingly."

Explore further: 'Liquid Biopsy': Blood test gives 'real-time' picture of cancer

Related Stories

'Liquid Biopsy': Blood test gives 'real-time' picture of cancer

May 31, 2012
(Medical Xpress) -- A simple and cost-effective blood test could be used to monitor how a patient is responding to treatment and detect genetic faults in their cancer as they happen, according to a Cancer Research UK study.

Another step toward resisting breast cancer

September 21, 2011
Medical researchers at the University of Leeds have come a step closer to understanding how to stop breast cancers from coming back.

Breast cancer gene provides vital clue to bowel cancer drug resistance

February 20, 2013
Having too many copies of a gene linked to breast cancer might be the reason why some bowel cancer patients fail to respond to certain targeted drugs, according to a study published in the British Journal of Cancer.

Reprogrammed oestrogen binding linked to more aggressive breast cancer

January 4, 2012
(Medical Xpress) -- Scientists based at Cancer Research UK’s Cambridge Research Institute have discovered how receptors for the female sex hormone oestrogen attach to a different part of the DNA in breast cancer patients ...

Scientists unravel resistance to breast cancer treatment

October 31, 2012
Scientists have identified a molecular 'flag' in women with breast cancer who do not respond or have become resistant to the hormone drug tamoxifen.

Recommended for you

Overcoming resistance to a standard chemotherapy drug

July 19, 2018
Despite being studied for decades, the chemotherapy drug cisplatin is revealing new aspects of how it works. Researchers at Winship Cancer Institute of Emory University have identified an enzyme responsible for making tumors ...

Complementary medicine for cancer can decrease survival

July 19, 2018
People who received complementary therapy for curable cancers were more likely to refuse at least one component of their conventional cancer treatment, and were more likely to die as a result, according to researchers from ...

Study finds melanoma biomarkers predicting checkpoint blocker response

July 18, 2018
Scientists at Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) have identified biomarkers in melanoma that could help tailor immunotherapy treatments to maximize the benefits for patients while reducing the likelihood ...

Scientists discover a mechanism of drug resistance in breast and ovarian cancer

July 18, 2018
There is a highly sophisticated way to treat some breast and ovarian cancers—a class of drugs called PARP inhibitors, designed to exploit the very defects that make tumors with certain mutations especially deadly. Yet this ...

Research identifies new breast cancer therapeutic target

July 18, 2018
Research led by Suresh Alahari, Ph.D., Professor of Biochemistry and Molecular Biology at LSU Health New Orleans School of Medicine, has shown for the first time that a tiny piece of RNA deregulates energy metabolism, an ...

Link found between bitter-taste sensitivity and cancer risk

July 18, 2018
High bitter-taste sensitivity is associated with a significantly increased risk of cancer in older British women, according to researchers who conducted a unique study of 5,500 women whose diet, lifestyle and health has been ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.